Literature DB >> 3102135

B lymphocyte activation by insoluble anti-mu antibodies in patients with systemic lupus erythematosus.

H Becker, U Schauer, K Helmke.   

Abstract

In order to study the capacity of anti-immunoglobulin (Ig) antibodies to induce proliferative responses in peripheral blood mononuclear cells (PBC) from patients with systemic lupus erythematosus (SLE), anti-mu coupled to Sepharose beads (anti-mu) was used as a polyclonal activator. In 18 patients, a strong proliferative response was associated with inactive disease, and the response was lower in clinical active disease (P less than 0.02). An inverse correlation could also be observed in six patients who were studied longitudinally (P less than 0.01). These results indicate that anti-mu responsiveness is closely related to disease activity in SLE. In addition, sequential data obtained from two patients during an early stage of clinical deterioration suggest that a low anti-mu response might be an early indicator of a clinical relapse. In the patients investigated, the anti-mu response was not correlated with the response to pokeweed mitogen (PWM), or with the quantity of B cells. When T cell depleted cell fractions were studied, marked increases in the proliferative responses to anti-mu were observed in some patients. These studies suggest that the response to anti-mu might be modified by T cells to a variable extent in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3102135      PMCID: PMC1542539     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  In vitro response of subpopulations of human lymphocytes. II. DNA synthesis induced by anti-immunoglobulin antibodies.

Authors:  P Gausset; G Delespesse; C Hubert; B Kennes; A Govaerts
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

2.  Activation of human B cells and inhibition of their terminal differentiation by monoclonal anti-mu antibodies.

Authors:  S Maruyama; H Kubagawa; M D Cooper
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

3.  The T cell dependence of B cell differentiation induced by pokeweed mitogen.

Authors:  R G Keightley; M D Cooper; A R Lawton
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

4.  Cellular DNA content of T helper, T suppressor and B lymphocytes in SLE.

Authors:  P Surányi; L Mátyus; I Sonkoly; G Szegedi
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

5.  Enzyme immunoassay for IgG and IgM antibodies against dsDNA and ssDNA.

Authors:  H Krippner; S Merle; K Pirlet
Journal:  Z Rheumatol       Date:  1983 Sep-Oct       Impact factor: 1.372

6.  The use of cytocentrifuge preparations for the demonstration of T cell surface antigens.

Authors:  M Salmon; P A Bacon; G D Johnson; L Walker; K W Walton
Journal:  J Immunol Methods       Date:  1984-02-10       Impact factor: 2.303

7.  Single step separation of human T and B cells using AET treated srbc rosettes.

Authors:  A Saxon; J Feldhaus; R A Robins
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

8.  Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides.

Authors:  R Axén; J Porath; S Ernback
Journal:  Nature       Date:  1967-06-24       Impact factor: 49.962

9.  Impaired B cell proliferation by Staphylococcus aureus Cowan 1 in patients with systemic lupus erythematosus.

Authors:  S Sawada; S Amaki; M Takei; M Karasaki; I Amaki
Journal:  Arthritis Rheum       Date:  1985-09

10.  Immunoglobulin synthesis by peripheral blood cells in systemic lupus erythematosus.

Authors:  H E Jasin; M Ziff
Journal:  Arthritis Rheum       Date:  1975 May-Jun
View more
  4 in total

1.  Imbalance of CD4+ lymphocyte subsets in patients with mixed connective tissue disease.

Authors:  H Becker; A Langrock; K Federlin
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Detection of circulating Fc epsilon R2/CD23+ monocytes in patients with rheumatic diseases.

Authors:  H Becker; P Potyka; C Weber; K Federlin
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

3.  Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin.

Authors:  H Becker; G Mitropoulou; K Helmke
Journal:  Klin Wochenschr       Date:  1989-03-01

4.  Analysis of proteins that interact with the IL-2 regulatory region in patients with rheumatic diseases.

Authors:  H Becker; G Stengl; M Stein; K Federlin
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.